Conference Highlights: IDSA 2010 Annual Meeting

The Infectious Diseases Society of America, or IDSA, held its 2010 annual meeting from October 21 to 24 in Vancouver. The features below highlight some of the news emerging from the meeting. » Comparing Treatments for Nosocomial Pneumonia » Earlier Treatment for HIV-Infected Patients Lagging » Analyzing Treatment Approaches for Cholera » Veterans Less Likely to Be Tested for HIV » The Link Between Smoking & Flu Risk in Children  Comparing Treatments for Nosocomial Pneumonia The Particulars: An estimated 1.7 million healthcare-associated infections are reported in American hospitals annually, and about 16% of those are associated with pathogens that are resistant to the antimicrobials traditionally used to treat them, including MRSA. Nosocomial pneumonia continues to be a significant cause of illness. When these infections are due to MRSA, treatment options are limited because there are few antibiotics that are effective against this resistant organism. Data Breakdown: A phase 4 study trial compared the efficacy and safety of linezolid with vancomycin in the treatment of nosocomial pneumonia proven to be caused by MRSA. Patients were randomized to receive linezolid IV 600 mg every 12 hours or vancomycin 15 mg/kg every 12 hours over the course of 7 to 14 days; vancomycin doses could be titrated at the investigator’s discretion based on creatinine clearance and vancomycin trough levels. Clinical success rates at the end of study were 57.6% for patients treated with linezolid compared with 46.6% for patients treated with vancomycin in the per-protocol group, the primary endpoint. Treatment-related adverse events, serious adverse events and deaths were comparable for linezolid and vancomycin. Take Home Pearl: Linezolid appears to achieve a statistically significantly higher clinical...